|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 October 2001, Vol. 98, No. 8, pp. 2584-2587
BRIEF REPORT
Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be
associated with warfarin sensitivity in Chinese patients
Anskar Y. H. Leung,
Howard C. H. Chow,
Y. L. Kwong,
Albert K. W. Lie,
Alvin T. K. Fung,
W. H. Chow,
Alex S. B. Yip, and
Raymond Liang
From the Division of Haematology and Oncology,
Department of Medicine, The University of Hong Kong.
CYP2C9 polymorphisms reported in Caucasians
(Arg144Cys in exon 3 and Ile359Leu in exon 7) are extremely
uncommon in Chinese persons. The genotype of CYP2C9 in this
population was characterized to investigate its relation with the
interindividual variation in warfarin dosages. Eighty-nine Chinese
patients receiving warfarin were recruited. Target sequences in
CYP2C9 in exons 1, 4, and 5 were amplified by polymerase
chain reaction, followed by direct sequencing. Polymorphisms at 4 positions were demonstrated in exon 4. Heterozygosities for 608TTG>GTG
(Leu208Val), 561CAG>CCG (Gln192Pro), 537CAT>CCT (His184Pro), and
527ATT>CTT (Ile181Leu) existed at frequencies 0.75, 0.20, 0.10, and
0.09, respectively. Seventeen patients (frequency, 0.19) were
homozygous for Val208. The common genotypic combinations at these loci
are Ile181/His184/Gln192/Leu208Val (n = 50),
Ile181/His184/Gln192/Val208 (n = 15),
Ile181/His184/Gln192/Leu208 (n = 4),
Ile181/His184/Gln192Pro/Leu208Val (n = 6),
Ile181/His184Pro/Gln192Pro/Leu208Val (n = 4), and
Ile181Leu/His184/Gln192Pro/ Leu208Val (n = 4). At codon 208, heterozygous Leu208Val and homozygous Val208 appeared to have a lower
warfarin dose requirement than the homozygous Leu208. Patients who are heterozygous for Ile181Leu had a
higher warfarin dose requirement than the homozygous Ile181. Amplified sequences in exons 1 and 5 did not exhibit polymorphism. In conclusion, Chinese patients showed genetic polymorphisms of CYP2C9 in
exon 4 and at codon 208; most were heterozygous Leu208Val and
homozygous Val208. Homozygous Leu208, a common allele in Caucasians, is
uncommon in this cohort. The significance of these CYP2C9
polymorphic alleles remains to be determined.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letters in Blood Online:
-
CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians
- Allan E. Rettie, Guoying Tai, David L. Veenstra, Fred M. Farin, Sengkeo Srinouanprachan, Yvonne S. Lin, Kenneth E. Thummel, and Ronald N. Hines
Blood 2003 101: 2896.
[Full Text]
[PDF]
-
No exon 4 polymorphism of cytochrome P450 CYP2C9 in Taiwanese
- Jan-Gowth Chang
Blood 2003 101: 5086-5087.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
C. M. Mosher, G. Tai, and A. E. Rettie
CYP2C9 Amino Acid Residues Influencing Phenytoin Turnover and Metabolite Regio- and Stereochemistry
J. Pharmacol. Exp. Ther.,
June 1, 2009;
329(3):
938 - 944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Hillman, R. A. Wilke, S. H. Yale, H. J. Vidaillet, M. D. Caldwell, I. Glurich, R. L. Berg, J. Schmelzer, and J. K. Burmester
A Prospective, Randomized Pilot Trial of Model-Based Warfarin Dose Initiation using CYP2C9 Genotype and Clinical Data
Clin. Med. Res.,
August 1, 2005;
3(3):
137 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-T. N Dang, J. Hambleton, and S. R Kayser
The Influence of Ethnicity on Warfarin Dosage Requirement
Ann. Pharmacother.,
June 1, 2005;
39(6):
1008 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kim, J. A. Johnson, and H. Derendorf
Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms
J. Clin. Pharmacol.,
October 1, 2004;
44(10):
1083 - 1105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Ma, A. N. Nafziger, and J. S. Bertino Jr.
Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers
J. Clin. Pharmacol.,
May 1, 2004;
44(5):
447 - 456.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. Takahashi, I. Ieiri, G. R. Wilkinson, G. Mayo, T. Kashima, S. Kimura, K. Otsubo, and H. Echizen
5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients
Blood,
April 15, 2004;
103(8):
3055 - 3057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-G. Chang
No exon 4 polymorphism of cytochrome P450 CYP2C9 in Taiwanese
Blood,
June 15, 2003;
101(12):
5086 - 5087.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Rettie, G. Tai, D. L. Veenstra, F. M. Farin, S. Srinouanprachan, Y. S. Lin, K. E. Thummel, and R. N. Hines
CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians
Blood,
April 1, 2003;
101(7):
2896 - 2896.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zarza, J. Hermida, R. Montes, I. Alberca, M. L. Lopez, and E. Rocha
Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population
Blood,
June 28, 2002;
100(2):
734 - 735.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hermida, J. Zarza, I. Alberca, R. Montes, M. L. Lopez, E. Molina, and E. Rocha
Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol
Blood,
May 13, 2002;
99(11):
4237 - 4239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Higashi, D. L. Veenstra, L. M. Kondo, A. K. Wittkowsky, S. L. Srinouanprachanh, F. M. Farin, and A. E. Rettie
Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy
JAMA,
April 3, 2002;
287(13):
1690 - 1698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
